Citi downgraded Reata Pharmaceuticals to Neutral from Buy with a price target of $172.50, up from $127, after Biogen (BIIB) agreed to acquire Reata for $172.50 per share in cash. The firm expects the deal to close “uneventfully” given that Biogen has no overlapping Friedreich’s ataxia franchise.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RETA:
- Reata Pharmaceuticals downgraded to Equal Weight from Overweight at Barclays
- Biotech Alert: Searches spiking for these stocks today
- Reata Pharmaceuticals price target raised to $173 from $85 at Baird
- Reata Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
- Reata downgraded to Market Perform from Outperform at SVB Securities
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue